[
  {
    "date": "2023-12-31",
    "symbol": "PPBT",
    "period": "FY",
    "cashandcashequivalents": 14489000,
    "shorttermdepositsclassifiedascashequivalents": 850000,
    "currentinvestments": 73000,
    "othercurrentassets": 376000,
    "currentassets": 15788000,
    "rightofuseassets": 316000,
    "propertyplantandequipment": 154000,
    "intangibleassetsotherthangoodwill": 28044000,
    "noncurrentassets": 28514000,
    "assets": 44302000,
    "currentleaseliabilities": 188000,
    "tradeandothercurrentpayablestotradesuppliers": 3532000,
    "othercurrentpayables": 3463000,
    "currentliabilities": 7183000,
    "noncurrentleaseliabilities": 163000,
    "noncurrentprovisionsforemployeebenefits": 141000,
    "noncurrentwarrantliability": 2518000,
    "noncurrentliabilities": 2822000,
    "sharepremium": 133184000,
    "receiptsonaccountsofwarrant": 28467000,
    "reserveofsharebasedpayments": 10088000,
    "capitalreserve": 761000,
    "otherreserves": 19000,
    "capitalreservefromtransactionswithnon-controllinginterest": -859000,
    "retainedearnings": -137453000,
    "equityattributabletoownersofparent": 34207000,
    "noncontrollinginterests": 0.0153,
    "equity": 34297000,
    "equityandliabilities": 44302000,
    "researchanddevelopmentexpense": 17034000,
    "sellinggeneralandadministrativeexpense": 5237000,
    "profitlossfromoperatingactivities": -22271000,
    "gainslossesonchangeinfairvalueofderivatives": -3497000,
    "financecosts": -2195000,
    "financeincome": -992000,
    "financeincomecost": -2294000,
    "profitlossfromcontinuingoperations": 19977000,
    "profitloss": 19977000,
    "othercomprehensiveincomebeforetaxcashflowhedges": -25000,
    "comprehensiveincome": 19952000,
    "profitlossattributabletoownersofparent": 19880000,
    "profitlossattributabletononcontrollinginterests": 97000,
    "comprehensiveincomeattributabletoownersofparent": 19855000,
    "comprehensiveincomeattributabletononcontrollinginterests": 97000,
    "basicearningslosspersharefromcontinuingoperations": 0.9,
    "basicearningslosspershare": 22133294,
    "dilutedearningslosspersharefromcontinuingoperations": 0.9,
    "dilutedearningslosspershare": 22133294,
    "issueofequity": 1045000,
    "adsissuedinconnectionwiththepurchaseofasubsidiary": 3781000,
    "increasedecreasethroughsharebasedpaymenttransactions": 1951000,
    "increasedecreasethroughtransactionswithowners": 6777000,
    "othercomprehensiveincomebeforetax": 25000,
    "adjustmentsfordepreciationexpense": 197000,
    "adjustmentsforfinanceincomecost": 2294000,
    "adjustmentsforsharebasedpayments": 1875000,
    "adjustmentsforreconcileprofitloss": -20199000,
    "adjustmentsfordecreaseincreaseinothercurrentassets": 178000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 1334000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": -1076000,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": -162000,
    "adjustmentsforchangesinassetsandliabilities": 274000,
    "cashflowsfromusedinoperatingactivitiescontinuingoperations": -19925000,
    "cashassumedaspartofacquisitionoffamewave": 3549000,
    "proceedsfromotherlongtermassetsclassifiedasinvestingactivities": 875000,
    "decreaseincreaseinshorttermdeposits": 15803000,
    "interestreceivedclassifiedasinvestingactivities": 755000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 3000,
    "cashflowsfromusedininvestingactivitiescontinuingoperations": 13881000,
    "proceedsfromissuingshares": 1563000,
    "paymentsforshareissuecosts": 229000,
    "proceedsfromissuingwarrants": 5000000,
    "warrantsissuanceexpensespaid": 661000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 168000,
    "interestpaidclassifiedasfinancingactivities": 56000,
    "cashflowsfromusedinfinancingactivitiescontinuingoperations": 5449000,
    "increasedecreaseincashandcashequivalents": -595000,
    "effectofexchangeratechangesoncashandcashequivalents": 54000,
    "descriptionofaccountingpolicyforbasisofconsolidationpolicytextblock": "A. Basis of consolidation",
    "disclosureofeffectofchangesinforeignexchangerates1textblock": "Data on exchange rates are as follows:",
    "scheduleofdiscontinuedoperationtabletextblock": "Consensi represented a separate major line of business. Discontinuation also included inventory write off. Consequently, the Company reportedConsensi as a discontinued operation and as of December 31, 2021 has one operating segment- oncology.",
    "scheduleofrecognizedamountsassetsacquiredandliabilitiesassumedtabletextblock": "The following table summarizes the recognizedamounts of assets acquired and liabilities assumed at the date of acquisition:",
    "disclosureofdetailedinformationaboutcashandcashequivalentexplanatorytabletextblock": "As of December 31,             2023      2022             USD thousands                     Balance in USD      14,007       11,902       Balance in other currencies      482       3,128       Total cash and cash equivalents      14,489       15,030",
    "disclosureofothercurrentassettextblock": "As of December 31,             2023      2022             USD thousands                            Government authorities      171       146       Prepaid expenses and other receivables      205       997       Total other current assets      376       1,143",
    "disclosureofdetailedinformationabouttradeandotherpayablesexplanatorytabletextblock": "As of December 31,             2023      2022             USD thousands                     Due to related parties - salary related      620       607       Accrued expenses      2,521       3,597       Government authorities      53       81       Salary related      269       437       Other payables      -       10              3,463       4,732",
    "disclosureofdetailedinformationaboutchangesinsharecapitalexplanatorytabletextblock": "Changes in share capital during the year",
    "disclosureofdetailedinformationaboutnoncontrollingintereststabletextblock": "The following table summarizes the informationrelating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations:",
    "disclosureofdetailedinformationaboutrestrictedstockunittabletextblock": "The number of RSUs are as follows:",
    "disclosureofdetailedinformationaboutsharebasedexpenserecognizedexplanatorytabletextbloc": "Expenses recognized in the consolidated financial statements:",
    "disclosureofrecordedexpensestoexecutiveofficerstabletextblock": "The Company recorded expenses to executive officers:",
    "disclosureofresearchanddevelopmentexpensestabletextblock": "For the year ended December 31             2023      2022      2021             USD thousands       Salaries, wages and related expenses      2,323       2,382       1,721       Share-based payments (see also Note 11)      768       768       557       Service providers      13,943       13,170       9,549                                             17,034       16,320       11,827",
    "scheduleoffinanceexpensesandincometabletextblock": "Finance expenses and income",
    "disclosureofdetailedinformationaboutemployeebenefitsexplanatorytabletextblock": "Employee benefits include post-employment benefits and short-term benefits.",
    "disclosureofdetailedinformationaboutdefinedcontributionplanexplanatorytabletextblock": "The Company has a defined contributionplan in respect of the Company’s liability in respect of its employees who are subject to Section 14 of the Severance Pay Law –1963.",
    "scheduleofdetailsregardingfairvaluemeasurementtabletextblock": "Financial asset- convertible note   Financial liability- warrant              Balance as of January 1, 2023   431    -   Issuance   -    6,015   Proceed   (875)   -   Revaluation   517    (3,497)  Balance as of December 31, 2023   73    2,518",
    "descriptionofnatureofobligationcontingentliabilities": "Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees",
    "descriptionoffullyamortisedintangibleassets": "The discounted cash flows method includes assumptions such as future expenses, future revenues, success rates (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate.",
    "closingforeignexchangesrate": 3,
    "cash": 44000,
    "otherintangibleassets": 7360000,
    "otherreceivables": 1000,
    "tradeandotherpayablestotradesuppliers": 28000,
    "otherpayables": 2000,
    "identifiableassetsacquiredliabilitiesassumed": 7375000,
    "depreciationrightofuseassets": 151000,
    "leaseliabilities": 188000,
    "interestexpenseonleaseliabilities": 37000,
    "governmentauthorities": 171000,
    "currentprepaidexpenses": 205000,
    "tradeandothercurrentpayablestorelatedparties": 620000,
    "currentaccruedexpensesandothercurrentliabilities": 2521000,
    "payabletogovernmentauthoritiescurrent": 53000,
    "payrollrelatedpayables": 269000,
    "numberofsharesauthorised": 1000000000,
    "numberofsharesissuedandfullypaid": 252379000,
    "numberofsharesissued": 25238000,
    "numberofissuanceshares": 6388000,
    "numberofvestingofrsus": 368000,
    "othernoncurrentassets": 6000,
    "currentasset": 247000,
    "currentliabiliti": -23419000,
    "netassetsliabilities": -23166000,
    "netassetsattributabletononcontrollinginterest": -355000,
    "profitlossfromcontinuingoperationsattributabletononcontrollinginterests": 6365000,
    "netassetsattributabletononcontrollinginterests": 97000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.46,
    "numberofoutstandingshareoptions": 19218782,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.62,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 10923032,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 0.54,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 2026452,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.19,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 2777000,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 5770750,
    "numberofinstrumentsotherequityinstrumentsgranted": 2777000,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 1187292,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 3676875,
    "exercisepriceshareoptionsgranted2019": 0.16,
    "exercisepriceoptionpricegranted2019": 0.19,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.7089,
    "descriptionofexpectedtermshareoptionsgranted": "P2Y",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.045,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2066000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 12000,
    "keymanagementpersonnelcompensationsharebasedpayment": 1346000,
    "keymanagementpersonnelcompensation": 3424000,
    "wagesandsalaries": 2323000,
    "sharebasedpayment": 768000,
    "serviceproviders": 13943000,
    "employeesandofficerscompensation": 1769000,
    "sharebasedcompensations": 822000,
    "reimbursementoflegalfees": -116000,
    "otherprofessionalfees": 1004000,
    "directorsremunerationexpense": 818000,
    "boardmembersharebasedpayments": 284000,
    "rentalexpense": 196000,
    "travelexpense": 130000,
    "depreciationexpense": 199000,
    "generalandadministrativeexpensesother": 131000,
    "feeandcommissionexpense": 56000,
    "gainslossesonexchangedifferencesontranslationnetoftax": -13000,
    "otherfinancecost": 2126000,
    "interestincomeondeposits": 474000,
    "changesinfairvalueoffinanceinstruments": 517000,
    "otherfinanceincome": 1000,
    "postemploymentbenefitexpensedefinedcontributionplans": 401000,
    "incomelossfromchangeinexchangeratedown": -11000,
    "incomelossvalue": 550000,
    "incomelossfromchangeinexchangerateup": -28000,
    "derivativefinancialassets": 73000,
    "derivativefinancialliabilities": 2518000,
    "fairvaluemeasurementbalance": 73000,
    "fairvaluemeasurementissuance": 6015000,
    "fairvaluemeasurementissuanceproceed": -875000,
    "fairvaluemeasurementrevaluation": 517000,
    "descriptionofoptionlifeshareoptiongranted": "P5Y3M18D",
    "discountforlackofmarketability": 0.261,
    "dilutiveeffectofwarrantsonweightedaveragenumberofordinaryshares": 10,
    "americandepositorysharespurchase": 1,
    "retainedearning": 137400000,
    "privateandpublicfinancingtotal": 101500000,
    "depreciationrightofuseassetsusefullife": "P5Y",
    "shareissuerelatedcost": 2215190,
    "sharesprice": 1.59,
    "percentageofdiscountsforlacksofmarketability": 0.108,
    "intangibleassetsrecoverableamountpercentage": 0.189,
    "ordinaryshares": 1000000000,
    "nonvotingseniorpreferredshares": 50000000,
    "preferredshares": 10000000,
    "fundsraisedamount": 1560000,
    "professionalfeesexpense": 1500000,
    "purchaseofcommonstockandwarrants": 3680,
    "warranttermdescription": "The October 2023 warrants have a term of five and a half years and have an exercise price of USD 1.25 per ADS",
    "otherexpensebynature": 761000,
    "salesagreementshares": 1044040,
    "weightedaverageshareprice2019": 1.63,
    "weighedaverageexercisepriceofshareoptionsvestinginperiodsharebasedpaymentarrangement": 0.19,
    "americandepostioryshares": 10,
    "optionoustanding": 6000,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P3Y1M6D",
    "monthlyfeeandservicedescription": "the Company pays the chairman of the board a monthly feefor his service as the chairman of our medical and clinical committee, and a monthly fee to one of the directors who has been engagedas an advisor in a 50% capacity.",
    "percentageofentitysrevenue": 0.03,
    "revenuefromroyalties": 5500000,
    "percentageofsublicenseconsideration": 0.12,
    "percentageofexitfee": 0.12,
    "licencefeeincome": 10000,
    "gainsonlitigationsettlements": 29000000,
    "warrantsexpireterm": "P5Y6M",
    "applicabletaxrate": 0.23,
    "statutorytaxrate": 0.23,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducedeferredtaxexpense": 4600000,
    "unrecognizedresearchanddevelopmentexpenses": 96000000,
    "employeebenefitbonus": 406000,
    "employeebenefitsliabilityduegrants": 141000,
    "borrowingsinterestrate": 0.01,
    "shorttermdepositsguaranteedforleasesandcredit": 139000,
    "shorttermdepositsguaranteedforhedgingtransactions": 700000,
    "issueofconvertibleinstruments": 625000,
    "financialinstrumentamount": 2518000,
    "entityregistrantname": "Purple Biotech Ltd.",
    "tradingsymbol": "PPBT",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 252379218,
    "amendmentflag": "false",
    "entitycentralindexkey": 1614744,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-37643",
    "entityincorporationstatecountrycode": "L3",
    "entityaddressaddressline1": "4 Oppenheimer Street",
    "entityaddressaddressline2": "Science Park",
    "entityaddresscityortown": "Rehovot",
    "entityaddresspostalzipcode": 7670104,
    "entityaddresscountry": "IL",
    "contactpersonnelname": "Lior Fhima",
    "cityareacode": 972,
    "localphonenumber": "3-933-3121",
    "contactpersonnelfaxnumber": "+972-3-5097196",
    "security12btitle": "American Depositary Shares, each representing 10 Ordinary Shares (1)",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1057,
    "auditorname": "KPMG International",
    "auditorlocation": "Tel-Aviv"
  },
  {
    "date": "2022-12-31",
    "symbol": "PPBT",
    "period": "FY",
    "cashandcashequivalents": 15030000,
    "shorttermdepositsnotclassifiedascashequivalents": 16652000,
    "tradereceivables": 431000,
    "othercurrentassets": 1143000,
    "currentassets": 33256000,
    "rightofuseassets": 467000,
    "propertyplantandequipment": 215000,
    "intangibleassetsotherthangoodwill": 20684000,
    "noncurrentassets": 21366000,
    "assets": 54622000,
    "currentleaseliabilities": 194000,
    "tradeandothercurrentpayablestotradesuppliers": 2132000,
    "othercurrentpayables": 4732000,
    "currentliabilities": 7058000,
    "noncurrentleaseliabilities": 321000,
    "noncurrentprovisionsforemployeebenefits": 145000,
    "noncurrentliabilities": 466000,
    "sharepremium": 126407000,
    "receiptsonaccountsofwarrant": 28017000,
    "reserveofsharebasedpayments": 10164000,
    "capitalreserve": 761000,
    "capitalreservefromhedging": -6000,
    "capitalreservefromtransactionswithnon-controllinginterest": -859000,
    "retainedearnings": -117573000,
    "equityattributabletoownersofparent": 46911000,
    "noncontrollinginterests": 0.015300000000000001,
    "equity": 187000,
    "equityandliabilities": 54622000,
    "researchanddevelopmentexpense": 16320000,
    "sellinggeneralandadministrativeexpense": 6283000,
    "operatingexpense": 22603000,
    "financecosts": 67000,
    "financeincome": 910000,
    "financeexpensesnet": -843000,
    "profitlossfromcontinuingoperations": 21760000,
    "profitloss": 92000,
    "lossfromcashflowhedge": 6000,
    "othercomprehensiveincome": 21766000,
    "profitlossattributabletoownersofparent": 21668000,
    "profitlossattributabletononcontrollinginterests": 92000,
    "profitlossattributabletoownersandincludingnoncontrollinginterests": 21760000,
    "comprehensiveincomeattributabletoownersofparent": 21674000,
    "comprehensiveincomeattributabletononcontrollinginterests": 92000,
    "totalcomprehensiveloss": 21766000,
    "basicanddilutedearningslossespershare": 1.2,
    "numberofsharesusedincalculatingbasicdilutedlossprofitperadsdiscontinuedoperation": 18081087,
    "dilutedlossperadsusd": 1.2,
    "numberofsharesusedincalculatingdilutedlossprofitperadsdiscontinuedoperation": 18081087,
    "issuanceofamericandepositorysharesnetofissuancecosts": 1346000,
    "increasedecreasethroughsharebasedpaymenttransactions": 2412000,
    "increasedecreasethroughtransactionswithowners": 3758000,
    "othercomprehensiveincomebeforetax": -6000,
    "adjustmentsfordepreciationexpense": 201000,
    "financeexpensesincomenet": -843000,
    "adjustmentsforsharebasedpayments": 2412000,
    "adjustmentsforreconcileprofitloss": -19990000,
    "adjustmentsfordecreaseincreaseinothercurrentassets": 313000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 799000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": 2132000,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 11000,
    "adjustmentsforchangesinassetsandliabilities": 3255000,
    "cashflowsfromusedinoperatingactivitiescontinuingoperations": -16735000,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 202000,
    "decreaseincreaseinshorttermdeposits": 19658000,
    "decreaseincreaseinlongtermdeposits": 160000,
    "interestreceivedclassifiedasfinancingactivities": 324000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 26000,
    "cashflowsfromusedininvestingactivitiescontinuingoperations": 19914000,
    "proceedsfromissuingshares": 1498000,
    "shareandadsissuanceexpensespaid": 152000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 165000,
    "interestpaidclassifiedasfinancingactivities": 67000,
    "cashflowsfromusedinfinancingactivitiescontinuingoperations": 1114000,
    "increasedecreaseincashandcashequivalents": 4293000,
    "effectofexchangeratechangesoncashandcashequivalents": -153000,
    "disclosuregeneraltextblock": "Note1 - General ",
    "descriptionofaccountingpolicyforbasisofconsolidationpolicytextblock": "  A. Basis of consolidation  ",
    "disclosureofdetailedinformationaboutexchangeratesandlinkagebasesexplanatorytabletextblock": "            Representative             exchange rate    of USD             (NIS/USD    1)       Date of consolidated financial statements:             December 31, 2022      3.519       December 31, 2021      3.110       December 31, 2020      3.215    ",
    "scheduleofintagileassets": "            2022      2021             USD    thousands       IPR&D related to TyrNovo (see    5A below)      6,172       6,172       IPR&D related to Famewave (see 5B below)      14,310       14,310       IPR&D related to    Purple GmbH      202       -                              Total intangible assets      20,684       20,482    ",
    "disclosureofdetailedinformationaboutcashandcashequivalentexplanatorytabletextblock": "            As    of December, 31             2022      2021             USD    thousands                     Balance in USD      11,902       9,174       Balance in other currencies      3,128       1,716       Total cash and cash equivalents      15,030       10,890   ",
    "scheduleofrecognizedinprofitorlosstabletextblock": "            2022      2021             USD    thousands      USD    thousands       Interest expenses    on lease liability      49       65   ",
    "disclosureofdetailedinformationaboutotherccrrentassetsexplanatorytabletextblock": "            As    of December, 31             2022      2021             USD    thousands                            Government authorities      146       268       Prepaid expenses and    other receivables      997       1,005       Total other current assets      1,143       1,273   ",
    "disclosureofdetailedinformationabouttradeandotherpayablesexplanatorytabletextblock": "            As    of December 31             2022      2021             USD    thousands                     Due to related parties - payroll    related      607       527       Accrued expenses      3,597       1,527       Government authorities      81       66       Payroll related      437       440       Other payables      10       18              4,732       2,578   ",
    "disclosureofdetailedinformationaboutchangesinsharecapitalexplanatorytabletextblock": "            For    the year ended December 31             2022      2021      2020             Number    of ADSs in thousands       Issued as at    January 1      17,800       17,211       1,956       Issuance    of ADSs (See D below)      544       126       8,573       Vesting of RSUs      138       163       7       Exercise    of warrants      -       300       6,675                                      Issued    as at December 31      18,482       17,800       17,211    ",
    "disclosureofdetailedinformationaboutnoncontrollingintereststabletextblock": "            December 31    2022      December 31     2021       TyrNovo    Ltd.     in    USD thousands                     Non-current assets      10       11       Current assets      428       976       Current liabilities      (17,240)      (11,806)      Net assets      (16,802)      (10,819)      Net assets attributable to non-controlling    interests      (258)      (166)      Loss for the year      5,983       5,467       Loss allocated to non-controlling interests      92       84   ",
    "disclosureofdetailedinformationaboutrestrictedstockunittabletextblock": "            Number    of RSUs             2022      2021       Outstanding at January 1      2,610,000       3,390,000       Granted during the year      6,785,000       1,020,000       Forfeited during the year      (157,083)      (166,250)      Vested during the year      (1,380,000)      (1,633,750)      Outstanding at December 31      7,857,917       2,610,000    ",
    "disclosureofdetailedinformationaboutsharebasedexpenserecognizedexplanatorytabletextbloc": "            For    the year ended  December 31             2022      2021      2020             USD    thousands       Research and development expenses      768       557       756       General and administrative    expenses      1,644       1,525       1,889                                      Total share-based expense    recognized      2,412       2,082       2,645   ",
    "disclosureofpaymentstokeymanagementexplanatorytabletextblock": "            For    the year ended December 31             2022      2021      2020             USD    thousands       Short - term employee benefits      2,623       2,402       1,982       Post-employment benefits      11       27       19       Share based payments      1,930       1,446       1,667                                             4,564       3,875       3,668    ",
    "disclosureofresearchanddevelopmentexpensestabletextblock": "            For    the year ended December 31             2022      2021      2020             USD    thousands       Salaries, wages and related expenses      2,382       1,721       1,209       Share-based payments (see also Note 11)      768       557       756       Service providers      13,170       9,549       5,273                                             16,320       11,827       7,238   ",
    "disclosureofdetailedinformationaboutemployeebenefitsexplanatorytabletextblock": "            For    the Year ended    December 31             2022      2021             USD    thousands      USD    thousands       Short-term    benefits      463       432       Post-employment benefit liabilities      145       292       Post-employment benefit    liabilities included in other payables      158       -    ",
    "disclosureofdetailedinformationaboutdefinedcontributionplanexplanatorytabletextblock": "            For    the Year ended December 31             2022      2021      2020             USD    thousands      USD    thousands      USD    thousands                                      Amount recognized as expense    in respect of defined contribution plan      390       291       197    ",
    "scheduleoffinancialinstrumentsmeasuredatfairvaluetabletextblock": "            December    31, 2022             Level    1      Level    2      Level    3      Total             USD    thousands       Financial asset                                  Convertible    debt instrument and warrant (see Note 19B (1))                                    431       431    ",
    "descriptionofnatureofobligationcontingentliabilities": "For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities",
    "descriptionoffullyamortisedintangibleassets": "See Note 5 regarding Intangible assets",
    "intangibleassetsandgoodwill": 20684000,
    "othercashandcashequivalents": 15030000,
    "depreciationrightofuseassets": 152000,
    "noncurrentleaseprepayments": 204000,
    "grossleaseliabilities": 388000,
    "leaseliabilities": 592000,
    "currentmaturitiesofleaseliability": 194000,
    "longtermleaseliability": 321000,
    "interestexpenseonleaseliabilities": 49000,
    "governmentauthorities": 146000,
    "prepaidexpensesandotherreceivables": 997000,
    "tradeandothercurrentpayablestorelatedparties": 607000,
    "currentaccruedexpensesandothercurrentliabilities": 3597000,
    "payabletogovernmentauthoritiescurrent": 81000,
    "payrollrelatedpayables": 437000,
    "otherpayable": 10000,
    "numberofsharesauthorised": 10000000,
    "numberofsharesissuedandfullypaid": 184815000,
    "numberofsharesissued": 18482000,
    "numberofissuanceshares": 544000,
    "numberofvestingofrsus": 138000,
    "othernoncurrentassets": 10000,
    "currentasset": 428000,
    "currentliabiliti": -17240000,
    "netassetsliabilities": -16802000,
    "netassetsattributabletononcontrollinginterest": -258000,
    "profitlossfromcontinuingoperationsattributabletononcontrollinginterests": 5983000,
    "netassetsattributabletononcontrollinginterests": 92000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.52,
    "numberofoutstandingshareoption": 18468235,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 0.82,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": -418068,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.28,
    "numberofshareoptiongrantedinsharebasedpaymentarrangement": 11135000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.97,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 6144318,
    "sharebasedpaymentarrangementsoutstandingrestrictedstockunits": 7857917,
    "sharebasedpaymentarrangementsrestrictedstockunitsgranted": 6785000,
    "sharebasedpaymentarrangementsoutstandingrestrictedstockunitsforfeited": -157083,
    "sharebasedpaymentarrangementsrestrictedstockunitsvested": -1380000,
    "descriptionofsharepriceshareoptionsgranted": 0.316,
    "descriptionofoptionpriceshareoptionsgrantedre": 0.304,
    "expectedvolatilitypercentage": 0.9626000000000001,
    "descriptionofexpectedtermshareoptionsgranted": 5,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.042800000000000005,
    "sharebasedcompensationresearchanddevelopmentexpense": 768000,
    "generalandadministrativeexpense": 1644000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 463000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 145000,
    "keymanagementpersonnelcompensationsharebasedpayment": 311000,
    "keymanagementpersonnelcompensation": 759000,
    "wagesandsalaries": 2382000,
    "sharebasedpayment": 768000,
    "serviceproviders": 13170000,
    "researchanddevelopmentexpenses": 16320000,
    "employeesandofficerscompensation": 1845000,
    "sharebasedcompensations": 1333000,
    "isasettlementseealsonote13b": 135000,
    "reimbursementoflegalfees": -63000,
    "otherprofessionalfees": 750000,
    "directorsremunerationexpense": 1152000,
    "boardmembersharebasedpayments": 311000,
    "rentalexpense": 120000,
    "travelexpense": 144000,
    "depreciationexpense": 201000,
    "generalandadministrativeexpensesother": 355000,
    "feeandcommissionexpense": 67000,
    "otherfinancecost": 67000,
    "interestincomeondeposits": 532000,
    "incomefromexchangeratedifferencesnet": -62000,
    "changesinfairvalueoffinanceinstruments": -245000,
    "otherfinanceincome": 71000,
    "financeincomecost": -910000,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 158000,
    "incomelossfromchangeinexchangerate": -21000,
    "incomelossvalue": -207000,
    "currentderivativefinancialliabilities": 431000,
    "significantunobservableinputsexpectedterm": 0.66,
    "significantunobservableinputsexpectedvolatility": 0.376,
    "significantunobservableinputsannualriskfreeinteres": 0.0447,
    "descriptionofwarrantstopurchaseamericandepositoryshares": "The Company’s securities (American Depository Shares (“ADS”)) were listed for trading on the NASDAQ in November 2015 (including a Series A warrant that expired in November 2020). Each ADS represents 10 ordinary shares with no par value following a reverse split in effect from August 23, 2020 (see Note 10A). Each 10 warrants enable the purchase of 1 ADS.",
    "retainedearning": 117600000,
    "privateandpublicfinancingtotal": 95800000,
    "depreciationrightofuseassetsusefullife": 5,
    "intangibleassetsrecoverableamountpercentage": 0.19399999999999998,
    "issuedsecuritiespublicofferingdescription": "A.",
    "salesagreementshares": 543400,
    "weightedaverageshareprice2019": 2.65,
    "fundsraisedamount": 1490000,
    "professionalfeesexpense": 1440000,
    "parvaluepershare": 4,
    "purchaseofcommonstockandwarrants": 140000,
    "exerciseofwarrantsequity": 10982000,
    "warrantsterm": 5,
    "investmentwarrantexerciseprice": 4.0625,
    "stockissuedduringperiodvalueissues": 315000,
    "derivativeinstrument": 9157000,
    "classofwarrantsorrighttitleofsecuritywarrantsorrightsoutstanding": "During 2022, the Company issued 1,380 thousand ordinary shares on account of vested RSUs granted in 2020 and 2021 to officers, board members and employees.",
    "stockoptionsgranted": 1463000,
    "weighedaverageexercisepriceofshareoptionsvestinginperiodsharebasedpaymentarrangement": 0.208,
    "vestingperiod": 3,
    "exerciseperiod": 5,
    "fairvalueofoptionsandgrantsmeasured": 2342000,
    "americandepostioryshares": 10,
    "optionoustanding": 6000,
    "percentageofentitysrevenue": 0.06,
    "descriptionofmaximumroyaltyamount": "As of December 31, 2022, the maximum royalty amount that would be payable by TyrNovo,excluding interest, is approximately NIS 5.5 million (USD 1.56 million), and as of such date, TyrNovo had not paid any royalties to theIIA.",
    "descriptionoflicenseagreement": "Inconsideration for the license grant, FameWave shall pay to THM the following during the term of the license: ",
    "applicabletaxrate": 0.23,
    "carryforwardlossesdescription": "In2022, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximatelyUSD 5 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of current yeartax losses and benefits.",
    "unrecognizedresearchanddevelopmentexpenses": 82000000,
    "employeebenefitbonus": 406000,
    "employeebenefitsliabilityduegrants": 303000,
    "shorttermdepositsclassifiedascashequivalents": 31682000,
    "borrowingsinterestrate": 0.052000000000000005,
    "shorttermdepositsguaranteedforleasesandcredit": 152000,
    "shorttermdepositsguaranteedforhedgingtransactions": 700000,
    "financialinstrumentamount": 431000,
    "aggregateamount": 94000000,
    "exceedamount": 100000000,
    "entityregistrantname": "Purple Biotech Ltd.",
    "tradingsymbol": "PPBT",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 184815092,
    "amendmentflag": "false",
    "entitycentralindexkey": 1614744,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-acceleratedfiler",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-37643",
    "entityincorporationstatecountrycode": "Israel",
    "entityaddressaddressline1": "4 Oppenheimer Street",
    "entityaddressaddressline2": "Science Park",
    "entityaddresscityortown": "Rehovot",
    "entityaddresspostalzipcode": 7670104,
    "entityaddresscountry": "Israel",
    "contactpersonnelname": "Lior Fhima",
    "localphonenumber": "3-933-3121",
    "cityareacode": 972,
    "contactpersonnelfaxnumber": "+972-3-5097196",
    "security12btitle": "American Depositary Shares, each representing 10 Ordinary Shares ",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "KPMG International",
    "auditorlocation": "Tel Aviv",
    "auditorfirmid": 1057
  },
  {
    "date": "2021-12-31",
    "symbol": "PPBT",
    "period": "FY",
    "cashandcashequivalents": 10890000,
    "shorttermdepositsnotclassifiedascashequivalents": 36310000,
    "othercurrentassets": 1273000,
    "currentassetsotherthanassetsordisposalgroupsclassifiedasheldforsaleorasheldfordistributiontoowners": 48473000,
    "investmentsinsubsidiariesjointventuresandassociates": 187000,
    "rightofuseassets": 619000,
    "propertyplantandequipment": 277000,
    "longtermdeposits": 160000,
    "intangibleassetsotherthangoodwill": 20482000,
    "assets": 70198000,
    "currentleaseliabilities": 199000,
    "tradeandothercurrentpayablestotradesuppliers": 1473000,
    "othercurrentpayables": 2578000,
    "currentliabilities": 4250000,
    "noncurrentleaseliabilities": 550000,
    "noncurrentprovisionsforemployeebenefits": 292000,
    "noncurrentliabilities": 842000,
    "sharepremium": 123951000,
    "receiptsonaccountsofwarrant": 28017000,
    "reserveofsharebasedpayments": 8862000,
    "capitalreserve": 761000,
    "capitalreservefromtransactionswithnon-controllinginterest": -859000,
    "retainedearnings": -95905000,
    "equityattributabletoownersofparent": 64827000,
    "noncontrollinginterests": 0.015300000000000001,
    "equity": 279000,
    "equityandliabilities": 70198000,
    "researchanddevelopmentexpense": 11827000,
    "sellinggeneralandadministrativeexpense": 6107000,
    "operatingexpense": 17934000,
    "financecosts": 212000,
    "financeincome": 320000,
    "financeexpensesnet": -108000,
    "profitlossfromcontinuingoperations": 17826000,
    "profitlossfromdiscontinuedoperations": 642000,
    "profitlossattributabletoownersofparent": 18384000,
    "profitlossattributabletononcontrollinginterests": 84000,
    "profitlossattributabletoownersandincludingnoncontrollinginterests": 18468000,
    "basicanddilutedearningslossespershare": 1.01,
    "basicanddilutedloss": 17568036,
    "basicdilutedlossprofitdiscontinuedoperation": 0.04,
    "numberofsharesusedincalculatingbasicdilutedlossprofitperadsdiscontinuedoperation": 17568036,
    "issuanceofamericandepositorysharesnetofissuancecosts": 540000,
    "increasedecreasethroughexerciseofwarrantsequity": 1200000,
    "increasedecreasethroughsharebasedpaymenttransactions": 2082000,
    "increasedecreasethroughtransactionswithowners": 3822000,
    "comprehensiveincome": -18468000,
    "profitloss": 17826000,
    "adjustmentsfordepreciationexpense": 231000,
    "financeexpensesincomenet": -108000,
    "adjustmentsforsharebasedpayments": 2082000,
    "adjustmentsforreconcileprofitloss": -15621000,
    "adjustmentsfordecreaseincreaseinothercurrentassets": -316000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 399000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": 634000,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 27000,
    "adjustmentsforchangesinassetsandliabilities": 744000,
    "cashflowsfromusedinoperations": -14877000,
    "decreaseincreaseinshortandlongtermdeposits": 13162000,
    "interestreceivedclassifiedasfinancingactivities": 359000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 115000,
    "cashflowsfromusedininvestingactivities": 13406000,
    "proceedsfromissuingshares": 564000,
    "shareandadsissuanceexpensespaid": 24000,
    "receiptsfromwarrantexercise": 1200000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 153000,
    "interestpaidclassifiedasfinancingactivities": 75000,
    "cashflowsfromusedinfinancingactivitiescontinuingoperations": 1512000,
    "cashflowsfromusedinoperatingactivities": -374000,
    "increasedecreaseincashandcashequivalents": -333000,
    "effectofexchangeratechangesoncashandcashequivalents": -24000,
    "disclosuregeneraltextblock": "Note1 - General ",
    "descriptionofaccountingpolicyforbasisofconsolidationpolicytextblock": "   A. Basis of consolidation  ",
    "disclosureofdetailedinformationaboutexchangeratesandlinkagebasesexplanatorytabletextblock": "            Representative             exchange rate of USD             (NIS/USD 1)       Date of consolidated financial statements:             December 31, 2021      3.110       December 31, 2020      3.215       December 31, 2019      3.456  ",
    "disclosureofdetailedinformationaboutcashandcashequivalentexplanatorytabletextblock": "            As of December 31             2021      2020             USD thousands                     Balance in USD      9,174       10,758       Balance in other currencies      1,716       489       Total cash and cash equivalents      10,890       11,247   ",
    "scheduleofrecognizedinprofitorlosstabletextblock": "            2021      2020             USD thousands      USD thousands       Interest expenses on lease liability      65       41   ",
    "disclosureofdetailedinformationaboutotherccrrentassetsexplanatorytabletextblock": "            As of December, 31             2021      2020             USD thousands                            Government authorities      268       197       Prepaid expenses and other receivables      1,005       780       Total other current assets      1,273       977   ",
    "disclosureofdetailedinformationabouttradeandotherpayablesexplanatorytabletextblock": "            As of December 31             2021      2020             USD thousands                     Due to related parties - payroll related      527       541       Accrued expenses      1,527       880       Government authorities      66       43       Payroll related      440       229       Other payables      18       -              2,578       1,693   ",
    "disclosureofdetailedinformationaboutnoncontrollingintereststabletextblock": "            December 31 2021      December 31  2020       TyrNovo Ltd.     in USD thousand                     Non-current assets      11       16       Current assets      976       174       Current liabilities      (11,806)      (5,543)      Net assets      (10,819)      (5,353)      Net assets attributable to non-controlling interests      (166)      (82)      Loss for the year      5,467       4,922       Loss allocated to non-controlling interests      84       75   ",
    "disclosureofdetailedinformationaboutrestrictedstockunittabletextblock": "            Number of RSUs             2021      2020       Outstanding at January 1      3,390,000       11,509       Granted during the year      1,020,000       3,601,972       Forfeited during the year      166,250       157,500       Vested during the year      1,633,750       65,981       Outstanding at December 31      2,610,000       3,390,000    ",
    "disclosureofdetailedinformationaboutsharebasedexpenserecognizedexplanatorytabletextbloc": "            For the year ended  December 31             2021      2020      2019             USD thousands       Research and development expenses      557       756       238       General and administrative expenses      1,525       1,889       1,035                                      Total share-based expense recognized      2,082       2,645       1,273   ",
    "disclosureofpaymentstokeymanagementexplanatorytabletextblock": "            For the year ended December 31             2021      2020      2019             USD thousands       Short - term employee benefits      2,402       1,982       1,776       Post-employment benefits      27       19       22       Share based payments      1,446       1,667       719                                             3,875       3,668       2,517    ",
    "disclosureofresearchanddevelopmentexpensestabletextblock": "            Forthe year ended December 31             2021      2020      2019             USD thousands       Salaries, wages and related expenses      1,721       1,209       804       Share-based payments (see also Note 11)      557       756       238       Service providers      9,549       5,273       1,236                                             11,827       7,238       2,278   ",
    "disclosureofdetailedinformationaboutemployeebenefitsexplanatorytabletextblock": "            For the Year ended December 31             2021      2020             USD thousands      USD thousands       Short-term benefits      432       263       Post-employment benefits      292       265    ",
    "disclosureofdetailedinformationaboutdefinedcontributionplanexplanatorytabletextblock": "            For the Year ended December 31             2021      2020      2019             USDthousands      USDthousands      USDthousands                                      Amount recognized as expense in respect of defined contribution plan      291       197       136    ",
    "scheduleoffinancialinstrumentsmeasuredatfairvaluetabletextblock": "            December 31, 2021             Level 1      Level 2      Level 3      Total             USD thousands       Financial asset                                  Convertible debt instrument (see Note 19B(1))                               187       187    ",
    "descriptionofnatureofobligationcontingentliabilities": "For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities",
    "descriptionoffullyamortisedintangibleassets": "See Note 5 regarding subsidiaries",
    "averageforeignexchangerate": 3.11,
    "changesinexchangerates": -0.03,
    "taxexpenserelatingtoprofitlossfromordinaryactivitiesofdiscontinuedoperations": 642000,
    "dilutedearningslosspersharefromdiscontinuedoperations": 0.04,
    "cashflowsfromusedinoperatingactivitiesdiscontinuedoperations": -374000,
    "cashflowsfromdiscontinuedoperation": -374000,
    "intangibleassetsandgoodwill": 20482000,
    "cash": 69000,
    "identifiableintangibleassetsrecognisedasofacquisitiondate": 14310000,
    "othercurrentreceivables": 6000,
    "tradeandotherpayablestotradesuppliers": 2283000,
    "otherpayables": 2102000,
    "identifiableassetsacquiredliabilitiesassumed": 10000000,
    "othercashandcashequivalents": 10890000,
    "depreciationrightofuseassets": 171000,
    "leaseliabilities": 877000,
    "currentmaturitiesofleaseliability": 199000,
    "longtermleaseliability": 550000,
    "interestexpenseonleaseliabilities": 65000,
    "governmentauthorities": 268000,
    "prepaidexpensesandotherreceivables": 1005000,
    "tradeandothercurrentpayablestorelatedparties": 527000,
    "currentaccruedexpensesandothercurrentliabilities": 1527000,
    "payabletogovernmentauthoritiescurrent": 66000,
    "payrollrelatedpayables": 440000,
    "otherpayable": 18000,
    "numberofsharesauthorised": 10000000,
    "numberofsharesissuedandfullypaid": 178001000,
    "numberofsharesissued": 17800000,
    "numberofissuanceshares": 126000,
    "numberofvestingofrsus": 163000,
    "numberofexerciseofwarrants": 300000,
    "noncurrentassets": 11000,
    "currentasset": 976000,
    "currentliabiliti": -11806000,
    "netassetsliabilities": -10819000,
    "netassetsattributabletononcontrollinginterest": -166000,
    "profitlossfromcontinuingoperationsattributabletononcontrollinginterests": 5467000,
    "netassetsattributabletononcontrollinginterests": 84000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.97,
    "numberofoutstandingshareoption": 7751303,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 1.52,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": -413074,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.47,
    "numberofshareoptiongrantedinsharebasedpaymentarrangement": 1170000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 1.48,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 4451430,
    "sharebasedpaymentarrangementsoutstandingrestrictedstockunits": 2610000,
    "sharebasedpaymentarrangementsrestrictedstockunitsgranted": 1020000,
    "sharebasedpaymentarrangementsoutstandingrestrictedstockunitsforfeited": 166250,
    "sharebasedpaymentarrangementsrestrictedstockunitsvested": 1633750,
    "descriptionofsharepriceshareoptionsgranted": 0.517,
    "descriptionofoptionpriceshareoptionsgrantedre": 0.492,
    "expectedvolatilitypercentage": 0.961,
    "descriptionofexpectedtermshareoptionsgranted": 5,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.01166,
    "sharebasedcompensationresearchanddevelopmentexpense": 557000,
    "generalandadministrativeexpense": 1525000,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 432000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 292000,
    "keymanagementpersonnelcompensationsharebasedpayment": 478000,
    "keymanagementpersonnelcompensation": 801000,
    "wagesandsalaries": 1721000,
    "sharebasedpayment": 557000,
    "serviceproviders": 9549000,
    "researchanddevelopmentexpenses": 11827000,
    "employeesandofficerscompensation": 1762000,
    "sharebasedcompensation": 1047000,
    "legalfee": 12000,
    "reimbursementoflegalfees": -66000,
    "otherprofessionalfees": 1222000,
    "directorsremunerationexpense": 1033000,
    "boardmembersharebasedpayments": 478000,
    "rentalexpense": 55000,
    "travelexpense": 133000,
    "depreciationexpense": 231000,
    "generalandadministrativeexpensesother": 200000,
    "feeandcommissionexpense": 79000,
    "gainslossesonexchangedifferencesontranslationnetoftax": 133000,
    "otherfinancecost": 212000,
    "postemploymentbenefitexpensedefinedcontributionplans": 291000,
    "incomelossfromchangeinexchangerate": -4000,
    "incomelossvalue": -292000,
    "currentderivativefinancialliabilities": 187000,
    "significantunobservableinputsexpectedterm": 2.75,
    "significantunobservableinputsexpectedvolatility": 1.25,
    "significantunobservableinputsannualriskfreeinteres": 0.0097,
    "descriptionofwarrantstopurchaseamericandepositoryshares": "The Company’s securities (American Depository Shares (“ADS”)) were listed for trading on the NASDAQ in November 2015 (including a Serries A warrant that expired in November 2020). Each ADS represents 10 ordinary shares with no par value following a reverse split in effect from August 23, 2020 (see Note 10A). Each 10 warrants enable the purchase of 1 ADS.",
    "retainedearning": 95900000,
    "privateandpublicfinancingtotal": 94400000,
    "descriptionoffunctionalcurrency": "These consolidated financial statements are presented inUS dollars (USD), which is the Group’s functional currency, rounded to the nearest one thousand, unless otherwise noted. The USDis the currency that represents the principal economic environment in which the Group operates. ",
    "descriptionoflosspershareads": "The accounting policies set out below have been consistently appliedfor all periods presented in these consolidated financial statements: ",
    "depreciationrightofuseassetsusefullife": 5,
    "numberofoperatingsegment": 1,
    "warrantsinvested": 3500000,
    "exchangeforadditional": 284553,
    "intangibleassetsrecoverableamountpercentage": 0.156,
    "issuedsecuritiespublicofferingdescription": "A.",
    "exerciseofwarrantsequity": 1273,
    "warrantexerciseprice": 300000,
    "classofwarrantsorrighttitleofsecuritywarrantsorrightsoutstanding": "During 2021, the Company issued 1,634 thousand ordinary shares on account of vested RSUs granted in 2020 to officers, board members and employees.",
    "stockoptionsgranted": 61000,
    "weighedaverageexercisepriceofshareoptionsvestinginperiodsharebasedpaymentarrangement": 0.346,
    "vestingperiod": 3,
    "exerciseperiod": 5,
    "fairvalueofoptionsandgrantsmeasured": 56000,
    "expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 1273000,
    "americandepostioryshares": 10000,
    "optionoustanding": 6000,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 3.9,
    "percentageofentitysrevenue": 0.06,
    "descriptionofmaximumroyaltyamount": "As of December 31, 2021, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5million (USD 1.8 million), and as of such date, TyrNovo had not paid any royalties to the IIA.",
    "maximumroyaltypayableexcludinginterest": 1800000,
    "descriptionoflicenseagreement": "In consideration for the license grant, FameWave shall pay to THMthe following during the term of the license: ",
    "feeandcommissionincome": 66000,
    "applicabletaxrate": 0.23,
    "carryforwardlossesdescription": "In 2021, the main reconciling item from thestatutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 4.2 million) to the effective tax rate(0%) is mainly due to the fact that deferred taxes were not created in respect of carry forward tax losses and in respect of unrecognizedexpenses for tax purposes such as changes in fair value of warrants.",
    "deferredtaxliabilities": 59000000,
    "employeebenefitbonus": 580000,
    "employeebenefitsliabilityduegrants": 292000,
    "shorttermdepositsclassifiedascashequivalents": 47360000,
    "borrowingsinterestrate": 0.001,
    "longtermdeposit": 160000,
    "fairvalueoffinancialinstrumentondiscontinuationofmeasurementatfairvaluethroughprofitorlossbecausecreditderivativeisusedtomanagecreditriskassets": 187000,
    "entityregistrantname": "Purple Biotech Ltd.",
    "tradingsymbol": "PPBT",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 178001092,
    "amendmentflag": "false",
    "entitycentralindexkey": 1614744,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "true",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-37643",
    "entityincorporationstatecountrycode": "Israel",
    "entityaddressaddressline1": "4 Oppenheimer Street",
    "entityaddressaddressline2": "Science Park",
    "entityaddresscityortown": "Rehovot",
    "entityaddresspostalzipcode": 7670104,
    "entityaddresscountry": "Israel",
    "contactpersonnelname": "Gil Efron",
    "contactpersonnelfaxnumber": "+972-3-5097196",
    "security12btitle": "American Depositary Shares, eachrepresenting 10 Ordinary Shares ",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "Somekh Chaikin",
    "auditorlocation": "Tel Aviv, Israel",
    "auditorfirmid": 1057,
    "cityareacode": 972,
    "localphonenumber": "3-933-3121"
  },
  {
    "date": "2020-12-31",
    "symbol": "PPBT",
    "period": "FY",
    "entityregistrantname": "Purple Biotech Ltd.",
    "entitycentralindexkey": 1614744,
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "documenttype": "20-F",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2020,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entityinteractivedatacurrent": "Yes",
    "entityincorporationstatecountrycode": "L3",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-37643",
    "entitycommonstocksharesoutstanding": 17210574,
    "icfrauditorattestationflag": "true",
    "cashandcashequivalents": 11247000,
    "shorttermdepositsnotclassifiedascashequivalents": 46558000,
    "tradereceivables": 500000,
    "othercurrentassets": 977000,
    "currentassets": 174000,
    "rightofuseassets": 790000,
    "propertyplantandequipment": 178000,
    "longtermdeposits": 3071000,
    "intangibleassetsotherthangoodwill": 20482000,
    "assets": 83803000,
    "currentleaseliabilities": 207000,
    "tradeandothercurrentpayablestotradesuppliers": 1198000,
    "othercurrentpayables": 1693000,
    "currentliabilities": -5543000,
    "noncurrentleaseliabilities": 688000,
    "noncurrentprovisionsforemployeebenefits": 265000,
    "noncurrentliabilities": 953000,
    "sharepremium": 118909000,
    "receiptsonaccountsofwarrant": 29984000,
    "reserveofsharebasedpayments": 8115000,
    "capitalreserve": 761000,
    "capitalreservefromtransactionswithnon-controllinginterest": -859000,
    "retainedearnings": -77521000,
    "equityattributabletoownersofparent": 79389000,
    "noncontrollinginterests": 363000,
    "equity": 363000,
    "equityandliabilities": 83803000,
    "revenue": 1000000,
    "researchanddevelopmentexpense": 757000,
    "sellinggeneralandadministrativeexpense": 6306000,
    "feeandcommissionincome": 182000,
    "operatingexpense": 13612000,
    "profitlossfromoperatingactivities": -12612000,
    "incomeexpensesfromreinsurancecontractsheldotherthanfinanceincomeexpenses": -15655000,
    "financecosts": 61000,
    "financeincome": 254000,
    "financeexpensesnet": 15462000,
    "profitlossfromcontinuingoperations": -28074000,
    "profitlossattributabletoownersofparent": 27999000,
    "profitlossattributabletononcontrollinginterests": 75000,
    "profitlossattributabletoownersandincludingnoncontrollinginterests": 28074000,
    "basicanddilutedearningslosspershare": 2.44,
    "basicanddilutedloss": 11500113,
    "issuanceofamericandepositorysharesnetofissuancecosts": 38748000,
    "increasedecreasethroughexerciseofwarrantsequity": 14688000,
    "increasedecreasethroughsharebasedpaymenttransactions": 2645000,
    "transferofderivativeinstrumentfromliabilitytoequity": 27386000,
    "adsandwarrantsissuedinconnectionwithpurchaseofsubsidiary": 13500000,
    "increasedecreasethroughtransactionswithowners": 96967000,
    "comprehensiveincome": -75000,
    "profitloss": 28074000,
    "adjustmentsfordepreciationexpense": 235000,
    "financeexpensesincomenet": 15462000,
    "adjustmentsforsharebasedpayments": 2645000,
    "adjustmentsforreconcileprofitloss": -9732000,
    "adjustmentsfordecreaseincreaseinothercurrentassets": 501000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -2330000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": -511000,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": -20000,
    "adjustmentsforchangesinassetsandliabilities": -2360000,
    "cashflowsfromusedinoperatingactivities": -12092000,
    "cashassumedaspartofacquisitionoffamewave": -69000,
    "cashandcashequivalentsinsubsidiaryorbusinessesacquiredordisposed2013": -49618000,
    "interestreceivedclassifiedasfinancingactivities": 110000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 156000,
    "cashflowsfromusedininvestingactivities": -49595000,
    "proceedsfromissuingshares": 27925000,
    "shareandadsissuanceexpensespaid": 2074000,
    "proceedsfromissuingwarrants": 26574000,
    "warrantsissuanceexpensespaid": 3281000,
    "receiptsfromwarrantexercise": 19547000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 179000,
    "interestpaidclassifiedasfinancingactivities": 24000,
    "cashflowsfromusedinfinancingactivities": 68488000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 6801000,
    "effectofexchangeratechangesoncashandcashequivalents": 61000,
    "reclassificationofnontradablederivativesuntilregisteredfortrading": 27386000,
    "privateandpublicfinancingtotal": 93800000,
    "averageforeignexchangerate": 3.215,
    "changesinexchangerates": -0.07,
    "depreciationrightofuseassetsusefullife": "P5Y",
    "lossprofitbeforesalesgeneralandadministrativeexpenses": 757000,
    "numberofreportablesegment": 2,
    "iprdrelatedtotyrnovo": 6172000,
    "iprdrelatedtofamewave": 14310000,
    "intangibleassetsandgoodwill": 20482000,
    "percentageofrecoverableamount": 0.15,
    "wagesandsalaries": 1209000,
    "sharebasedpayments": 756000,
    "serviceproviders": 5523000,
    "depreciationrightofuseassets": -233000,
    "changeduringyeartorightofuseassets": 817000,
    "leaseliabilities": 840000,
    "shorttermleaseliability": 207000,
    "longtermleaseliability": 688000,
    "interestexpenseonleaseliabilities": 41000,
    "governmentauthorities": 197000,
    "prepaidexpensesandotherreceivables": 780000,
    "tradeandotherpayablestorelatedparties": 541000,
    "currentaccruedexpensesandothercurrentliabilities": 880000,
    "payabletogovernmentauthoritiescurrent": 43000,
    "payrollrelatedpayables": 229000,
    "numberofsharesauthorised": 10000000,
    "numberofsharesissuedandfullypaid": 172106000,
    "numberofsharesissued": 17211000,
    "numberofissuanceofadsshares": 8573000,
    "numberofvestingofrsus": 7000,
    "numberofexerciseofwarrants": 6675000,
    "proportionofownershipinterestsheldbynoncontrollinginterests": 0.0153,
    "noncurrentassets": 16000,
    "netassetsliabilities": -5353000,
    "netassetsattributabletononcontrollinginterests": -82000,
    "profitlossfromcontinuingoperationsattributabletononcontrollinginterests": 4922000,
    "professionalfeesexpense": 1315000,
    "stockissuedduringperiodsharesissues": 129861,
    "issuedsecuritiespublicofferingdescription": "The Company’s authorized share capital is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class.",
    "weightedaverageexercisepriceofshareoptionoutstandinginsharebasedpaymentarrangement": 1.02,
    "weightedaverageexercisepriceofshareoptionexpiredinsharebasedpaymentarrangement": 0.23,
    "weightedaverageexercisepriceofshareoptiongrantedinsharebasedpaymentarrangement": 0.43,
    "weightedaverageexercisepriceofshareoptionexercisableinsharebasedpaymentarrangement": 1.54,
    "numberofoutstandingshareoption": 6994377,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": 1486125,
    "numberofshareoptiongrantedinsharebasedpaymentarrangement": 3725826,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 1753632,
    "sharebasedpaymentarrangementsoutstandingrestrictedstockunits": 3390000,
    "sharebasedpaymentarrangementsrestrictedstockunitsgranted": 3601972,
    "sharebasedpaymentarrangementsoutstandingrestrictedstockunitsforfeited": 157500,
    "sharebasedpaymentarrangementsrestrictedstockunitsvested": 65981,
    "descriptionofsharepriceshareoptionsgranted": 0.898,
    "descriptionofoptionpriceshareoptionsgranted": 1.98,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.07,
    "descriptionofexpectedtermshareoptionsgranted": "P7Y0M0D",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.005,
    "sharebasedcompensationresearchanddevelopmentexpense": 756000,
    "generalandadministrativeexpense": 1889000,
    "keymanagementpersonnelcompensation": 1048000,
    "weightedaverageexercisepriceofshareoptionsvestinginperiodsharebasedpaymentarrangement": 6,
    "weightedaverageremainingcontractuallife": "P5Y10M21D",
    "keymanagementpersonnelcompensationsharebasedpayment": 2049000,
    "explanationofmodificationsmodifiedsharebasedpaymentarrangements": "The Company recorded in 2020 an expense of USD 2,645 thousand (2019 - USD 1,273 thousand, 2018- USD 719 thousand), of which USD 2,409 thousand (2019 - USD 988 thousand, 2018 - USD 660 thousand) are to officers and directors.",
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 263000,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 265000,
    "descriptionoflicenseagreement": "In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.",
    "percentageofentitysrevenue": 0.06,
    "licencefeeincome": 10000000,
    "employeeandofficercompensation": 1355000,
    "paymentsforshareissuecosts": 1147000,
    "legalfee": 43000,
    "directorsremunerationexpense": 962000,
    "boardmembersharebasedpayments": 742000,
    "rentalexpense": 58000,
    "travelexpense": 76000,
    "depreciationexpense": 235000,
    "generalandadministrativeexpensesother": 373000,
    "feeandcommissionexpense": 56000,
    "gainslossesonexchangedifferencesontranslationnetoftax": 5000,
    "otherfinancecost": 61000,
    "applicabletaxrate": 0.23,
    "deferredtaxliabilities": 41000000,
    "taxesonincomedescription": "In 2020, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 6.4 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of carry forward tax losses",
    "postemploymentbenefitexpensedefinedcontributionplans": 197000,
    "employeebenefitbonus": 481000,
    "employeebenefitsliabilityduegrants": 265000,
    "incomelossfromchangeinexchangerate": -40000,
    "incomelossvalue": -265000,
    "significantunobservableinputsexpectedterm": "P5Y3M19D",
    "significantunobservableinputsexpectedvolatility": 1.0717,
    "significantunobservableinputsannualriskfreeinterest": 0.004,
    "shorttermdepositsclassifiedascashequivalents": 60876000,
    "borrowingsinterestrate": 0.012,
    "longtermdeposit": 71000
  }
]